Valuation : NEOVACS

Market Cap 4.09K 4.75K 3.84K 3.5K 6.58K 452K 6.63K 45.5K 17.7K 229K 17.83K 17.44K 759K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -233K -189K -172K -324K -22.21M -326K -2.24M -870K -11.26M -877K -857K -37.29M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day+0.91%
1 week-34.45%
Current month-45.21%
1 month-45.21%
3 months-90.00%
6 months-97.33%
Current year-99.54%
1 week 0.38
Extreme 0.3824
0.62
1 month 0.38
Extreme 0.3824
1.43
Current year 0.38
Extreme 0.3824
267
1 year 0.38
Extreme 0.3824
6,780
3 years 0.38
Extreme 0.3824
32,000,000
5 years 0.38
Extreme 0.3824
351,920,000
10 years 0.38
Extreme 0.3824
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
2/27/21 A Sell

Chief Executive Officer

2,505,144 1.3796%
2/23/21 A Sell

Chief Executive Officer

6,391,053 3.5196%
2/23/21 A Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%-34.45%-99.99%-100.00% 73.17K
-1.23%-1.91%+0.98%+17.94% 50.47B
-1.92%-3.72%+415.33%+499.68% 44.56B
-0.45%+0.09%+41.77%+17.00% 43.08B
-2.48%-3.93%+7.62%+72.18% 41.7B
-0.94%-1.77%+18.34%+46.84% 33.21B
-1.69%-4.90%+24.57%+118.17% 16.77B
+6.81%+4.83% - - 16.28B
+0.25%-0.98%+11.63%+27.62% 14.58B
-1.87%-4.13%+77.52%+38.41% 13.92B
Average -0.23%-4.64%+55.31%+81.98% 27.46B
Weighted average by Cap. -0.85%-1.05%+88.83%+121.52%

Financials

2023 2024
Net sales 533K 620K 501K 457K 859K 58.95M 865K 5.93M 2.31M 29.89M 2.33M 2.28M 98.97M 434K 504K 407K 372K 699K 47.95M 704K 4.83M 1.88M 24.32M 1.89M 1.85M 80.52M
Net income -8.74M -10.15M -8.21M -7.49M -14.08M -966M -14.18M -97.28M -37.85M -490M -38.13M -37.3M -1.62B -32.91M -38.23M -30.91M -28.21M -53M -3.64B -53.38M -366M -142M -1.84B -144M -140M -6.11B
Net Debt -237K -275K -222K -203K -381K -26.14M -384K -2.63M -1.02M -13.25M -1.03M -1.01M -43.88M -205K -238K -193K -176K -330K -22.66M -333K -2.28M -888K -11.49M -894K -875K -38.05M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
31/08/26 0.4000 +0.91% 30,179
28/08/26 €0.3964 -0.92% 37,658
27/08/26 €0.4001 -4.74% 51,473
26/08/26 €0.4200 -23.64% 93,428
25/08/26 €0.5500 -9.87% 44,805
  1. Stock Market
  2. Stocks
  3. ALNEV Stock